The LAMEA prazosin market is estimated to grow significantly during the forecast period. The factors contributing to the growth of the indapamide market include rising cases of diabetes and hypertension among the population. According to the International Diabetes Federation (IDF), Brazil and Mexico are the two countries with a higher number of diabetes cases registered in the region. In Mexico, an estimated 12 million cases were registered in 2017. Additionally, the diabetes cases are expected to rise by 35% to an estimated 16 million cases by 2045 in Mexico. Moreover, according to the World Health Organization (WHO), diabetes is the second-most common cause of mortality in Mexico. Hence, indapamide drugs have great potential to offer for diabetes in the market of the RoW region. Some of the major factors that are contributing to the increasing cases of diabetes include rapid urbanization and changing lifestyles across the region.
Get Free Sample link @ https://www.omrglobal.com/request-sample/lamea-indapamide-market
The LAMEA indapamide market is segmented on the basis of product and application. Based on the product, the market is bifurcated into 1.25 mg indapamide and 2.5 mg indapamide. Among these, the market for 1.25 mg medicine held a significant share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have a significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
A full report of Latin America and Middle & Africa (LAMEA) Indapamide Market available @ https://www.omrglobal.com/industry-reports/lamea-indapamide-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
LAMEA Indapamide Market by Product
- 25 MG
- 5 MG
LAMEA Indapamide Market by Application
- High Blood Pressure
- Heart Failure
- Others
Regional Analysis
- Latin America
- Middle East
- Africa
Company Profiles
- ANI Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Ltd.
- Grupo Azevedos
- Krka Group
- Mylan N.V.
- Merck KGaA
- Sanofi S.A.
- Sandoz International GmbH
- Servier Group
- Teva Pharmaceuticals Industries Ltd.
The Report Covers
- Comprehensive research methodology of the LAMEA Indapamide market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the LAMEA Indapamide market.
- Insights about market determinants which are stimulating the LAMEA Indapamide market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/lamea-indapamide-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
